LSU-LCMC Gynecologic Oncology Clinical Trials
Cervical
- A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer
- A Phase 2 Study of Avutometinib (VS-6766; Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (OU-SCC-DURAFAK)
- A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
- Induction Pembrolizumab and Chemotherapy followed by Pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer.
Endometrial and Uterine
- A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer
- An open label phase II study of the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer
- A Phase 2 Study of Avutometinib (VS-6766; Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (OU-SCC-DURAFAK)
- A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
- A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma
- A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
- A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Ovarian cancer
- A Phase 2 Study of Avutometinib (VS-6766; Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (OU-SCC-DURAFAK)
- A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
- VS-6766-301 (GOG-3097; ENGOT-ov81/NCRI) A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
- Phase 3 Trial Evaluating the Safety and Efficacy of IMNN-001 Administered in Combination with Standard NACT and Adjuvant Chemotherapy in Newly Diagnosed Patients with Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (OVATION-3)
Miscellaneous
- A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
- Blinded Reference Set For Multicancer Early Detection Blood Tests
- Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
- Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
- Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON)
- Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
- Longitudinal Observation Trial to Uncover Subtypes of Cancer Cachexia
Phase I
- A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants with Advanced Solid Tumors
- First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- A study of a selective ERBB2 inhibitor, GCT4255, in patients with advanced solid tumors with ERBB2 genetic alterations or HER2 overexpression
- A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) Alone or in Combination with Standard of Care Therapy in Participants with Advanced Solid Malignancies